Howard Hendrickson
Assistant Professor
Department of Pharmaceutical Sciences
Phone: (501) 603-1547
Office: Education II Bldg 6/110G
Email: hendricksonhowardp@uams.edu

Research Interests
Exciting challenges exist in the development of high-throughput analytical techniques capable of addressing problems identified by recent advances in the areas of pharmaceutical and drug discovery research. In general, we concern ourselves with improving the speed of analysis beginning with sampling process and ending with the data analysis. Our primary goal is to develop a general approach to analytical methods development that is based the physical and chemical properties of drug candidates. Of particular interest to my research group is the discovery and validation disease markers, through targeted metabolomics.

Teaching:
Pharmaceutics
Pharmaceutical Analysis

Recent Publications

Gupta, Prem; Brown, Joshua; Biju, Prabath; Thaden, John; Deutz, Nicolaas; Kumar, K; Hauer-Jensen, Martin; Hendrickson, Howard; Development of high-throughput HILIC-MS/MS methodology for plasma citrulline determination in multiple species. Analytical Methods, 2011 2, 1759 – 1768.

Sarah White, Elizabeth Laurenzana, Howard Hendrickson, W. Brooks Gentry and S. Michael Owens, Gestation time-dependent pharmacokinetics of intravenous (+)-methamphetamine and (+)-amphetamine in rats, Drug Metabolism and Disposition, 2011, DOI:10.1124/dmd.111.039446

Krishna C. Chimalakonda, Chris Hailey, Ryan Black, Allison Beekman, Rebecca Carlisle, Elizabeth Lowman-Smith, Heather Singletary, S. Michael Owens, and Howard P. Hendrickson, Development and validation of an LC-MS/MS method for determination of phencyclidine in human serum and blood and its application to human drug abuse cases, Analytical Methods, 2010, 2, 1249 - 1254.

Laurenzana EM, Hendrickson HP Carpenter D, Peterson EC Gentry WB, West M Che YN, Carroll FI, Owens SM Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats, Vaccine, 2009, 27, 7011-7020.

Sarah J. White, Elizabeth M. Laurenzana, W. Brooks Gentry, Howard P. Hendrickson, D. Keith Williams, Keith W. Ward, and S. Michael Owens, Vulnerability to (+)-Methamphetamine Effects and the Relationship to Drug Disposition in Pregnant Rats during Chronic Infusion, Toxicological Sciences, 2009 111, 27-36.

Gupta Prem, Hubbard Martha A, Gurley Bill J, Hendrickson Howard P, Validation of a liquid chromatography-tandem mass spectrometric assay for the quantitative determination of hydrastine and berberine in human serum, Journal of Pharmaceutical and Biomedical Analysis 2009 49, 1021–1026.

Current Research Support

1. 2R44AT003365-02 (Hendrickson, Beavers, and Cech)
Development of Research Grade Goldenseal Phase II           9/1/2011 – 8/31/2012  2.4 CM

NIH/NCCAM (NIDDK)                                $607,949

The purpose of these studies is to produce a research grade form of a botanical product derived from Hydrastis canadensis. Dr. Hendrickson’s primary responsibilities in this multiple PI grant is to determine key physicochemical properties of four different Hydrastis formulations.

2. UAMS Medical Research Endowment Award (Hendrickson)

Pharmacokinetic-Pharmacodynamic modeling of Cyclomydril in Preterm Infants
1/01/2011 - 6/30/2013                                     $8,200                                     0.12 CM

The major goal of this project is to develop a blood-dried-spot diagnostic tools for the assessment of apnea in pre-term infants following an eye-exam.

3. U01 DA023900-01 (Owens)                    9/1/2011 - 8/31/2012               1.2 CM
Active immunization for treating methamphetamine abuse
NIH/NIDA                                                     $757,514

The purpose of these preclinical studies is to facilitate the medical discovery and development of new (+)METH-conjugate vaccines (MCVs) to help patients stop using (+)METH-like drugs by blocking or reducing their effects even under challenges of binge and relapse.

4. R01 DA026423-01 (Peterson)                  4/1/2011 – 3/30/2012

The major goal of this project is to produce anti-methamphetamine single chain variable antibody fragments (scFv) conjugated to a dendrimer delivery system and to examine the pharmacokinetic properties of the resulting “dendribodies” in a rodent model. Dr. Hendrickson is responsible for overseeing the analytical analysis of all METH pharmacokinetic and pharmacodynamic samples by LC-MS/MS.

5. HU0001-09-1-0005 #671558 (Kumar & Hauer-Jensen, Co-PIs) 1/25/2010 − 1/24/2013

1. Defense Threat Reduction Agency                $197,241                                 1.2 CM

Synergistic Radioprotection of Gastrointestinal Tract by Gamma-Tocotrienol and Statins: Efficacy and Mechanisms.

The major goal of this project is to investigate whether the combination of gamma-tocotrienol and statins result in improved radioprotection compared to gamma-tocotrienol alone.